Movement Alert｜Vaxcyte, Inc. Intraday Rise 5.04% in Regular Trading, target price raised after positive Phase 3 vaccine data

Market Focus10-20

On October 20, Vaxcyte, Inc. rose 5.04% in Regular Trading, trading near $66.81, with turnover of $44.45 million.

The move coincided with a clear event-driven catalyst: after the company reported that its adult pivotal Phase 3 OPUS-1 trial showed VAX-31 met all pre-specified primary endpoints, Needham raised its price target to $122 from $110 and maintained a Buy rating.

Background disclosures indicated VAX-31 achieved all primary endpoints across studied age groups versus Prevnar 20 and/or Capvaxive, while showing favorable safety and tolerability. The company said results from two additional adult Phase 3 trials are expected in the first half of 2027, supporting a planned BLA submission to the FDA in the first half of 2028. Those developments provide the main published basis for the latest share rise.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment